Voltar
Artigo Acesso aberto Revisado por pares
BIBTEX RIS

Comparable safety profile of BeEAM (bendamustine, etoposide, cytarabine, melphalan) and BEAM (carmustine, etoposide, cytarabine, melphalan) as conditioning before autologous haematopoietic cell transplantation

2018; Termedia Publishing House; Volume: 22; Issue: 2 Linguagem: Inglês

10.5114/wo.2018.77046

ISSN

1897-4309

Autores

Andrzej Frankiewicz, Maria Saduś‐Wojciechowska, Jacek Najda, Tomasz Czerw, Włodzimierz Mendrek, Małgorzata Sobczyk‐Kruszelnicka, Katarzyna Soska, Małgorzata Ociepa-Wasilkowska, Jerzy Hołowiecki, Sebastian Giebel,

Tópico(s)

Chronic Lymphocytic Leukemia Research

Resumo

ENWEndNote BIBJabRef, Mendeley RISPapers, Reference Manager, RefWorks, Zotero AMA Frankiewicz A, Saduś-Wojciechowska M, Najda J, et al. Comparable safety profile of BeEAM (bendamustine, etoposide, cytarabine, melphalan) and BEAM (carmustine, etoposide, cytarabine, melphalan) as conditioning before autologous haematopoietic cell transplantation. Contemporary Oncology/Współczesna Onkologia. 2018;22(2):113-117. doi:10.5114/wo.2018.77046. APA Frankiewicz, A., Saduś-Wojciechowska, M., Najda, J., Czerw, T., Mendrek, W., & Sobczyk-Kruszelnicka, M. et al. (2018). Comparable safety profile of BeEAM (bendamustine, etoposide, cytarabine, melphalan) and BEAM (carmustine, etoposide, cytarabine, melphalan) as conditioning before autologous haematopoietic cell transplantation. Contemporary Oncology/Współczesna Onkologia, 22(2), 113-117. https://doi.org/10.5114/wo.2018.77046 Chicago Frankiewicz, Andrzej, Maria Saduś-Wojciechowska, Jacek Najda, Tomasz Czerw, Włodzimierz Mendrek, Małgorzata Sobczyk-Kruszelnicka, and Katarzyna Soska et al. 2018. "Comparable safety profile of BeEAM (bendamustine, etoposide, cytarabine, melphalan) and BEAM (carmustine, etoposide, cytarabine, melphalan) as conditioning before autologous haematopoietic cell transplantation". Contemporary Oncology/Współczesna Onkologia 22 (2): 113-117. doi:10.5114/wo.2018.77046. Harvard Frankiewicz, A., Saduś-Wojciechowska, M., Najda, J., Czerw, T., Mendrek, W., Sobczyk-Kruszelnicka, M., Soska, K., Ociepa, M., Hołowiecki, J., and Giebel, S. (2018). Comparable safety profile of BeEAM (bendamustine, etoposide, cytarabine, melphalan) and BEAM (carmustine, etoposide, cytarabine, melphalan) as conditioning before autologous haematopoietic cell transplantation. Contemporary Oncology/Współczesna Onkologia, 22(2), pp.113-117. https://doi.org/10.5114/wo.2018.77046 MLA Frankiewicz, Andrzej et al. "Comparable safety profile of BeEAM (bendamustine, etoposide, cytarabine, melphalan) and BEAM (carmustine, etoposide, cytarabine, melphalan) as conditioning before autologous haematopoietic cell transplantation." Contemporary Oncology/Współczesna Onkologia, vol. 22, no. 2, 2018, pp. 113-117. doi:10.5114/wo.2018.77046. Vancouver Frankiewicz A, Saduś-Wojciechowska M, Najda J, Czerw T, Mendrek W, Sobczyk-Kruszelnicka M et al. Comparable safety profile of BeEAM (bendamustine, etoposide, cytarabine, melphalan) and BEAM (carmustine, etoposide, cytarabine, melphalan) as conditioning before autologous haematopoietic cell transplantation. Contemporary Oncology/Współczesna Onkologia. 2018;22(2):113-117. doi:10.5114/wo.2018.77046.

Referência(s)